Document is current

Any future updates will be listed below

Correction to: Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study

Crossref DOI link: https://doi.org/10.1007/s12185-021-03091-0

Published Online: 2021-02-18

Published Print: 2021-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark